The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVH | -64.73% | -23.55% | -5.23% | -57% |
| S&P | +15.06% | +95.03% | +14.29% | +222% |
Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.
Investors are applauding the clinical and administrative services company's latest acquisition.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $444.33M | -31.3% |
| Gross Profit | $76.94M | 0.4% |
| Gross Margin | 17.32% | 5.5% |
| Market Cap | $1.32B | -40.5% |
| Market Cap / Employee | $0.29M | 0.0% |
| Employees | 4.5K | -4.3% |
| Net Income | -$19.90M | -1346.7% |
| EBITDA | $27.25M | -32.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $175.36M | 44.6% |
| Accounts Receivable | $358.76M | -4.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $885.67M | 8.8% |
| Short Term Debt | $196.33M | 3101.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -5.29% | -2.4% |
| Return On Invested Capital | -9.77% | 4.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$39.10M | -373.2% |
| Operating Free Cash Flow | -$30.33M | -241.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.08 | 1.25 | 1.09 | 1.39 | -33.34% |
| Price to Sales | 1.32 | 0.51 | 0.46 | 0.59 | -36.22% |
| Price to Tangible Book Value | -4.19 | -1.63 | -1.33 | -1.50 | -45.26% |
| Price to Free Cash Flow TTM | 39.47 | 33.96 | 16.80 | 36.44 | - |
| Enterprise Value to EBITDA | 227.03 | 68.03 | 70.10 | 81.15 | 13.50% |
| Free Cash Flow Yield | 2.5% | 2.9% | 6.0% | 2.7% | - |
| Return on Equity | -6.8% | -6.0% | -11.0% | -13.4% | 93.03% |
| Total Debt | $822.37M | $903.85M | $1.06B | $1.08B | 31.96% |
EVH earnings call for the period ending December 31, 2024.
EVH earnings call for the period ending September 30, 2024.
EVH earnings call for the period ending June 30, 2024.
EVH earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
